Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atrasentan - Abbvie

Next Previous
Drug Profile

Atrasentan - Abbvie

Alternative Names: A 147627; A-1476271; Abbott 147627; ABT-147627; ABT-627; Atrasentan hydrochloride; Xinlay

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Amides; Antineoplastics; Benzodioxoles; Carboxylic acids; Pyrrolidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic nephropathies
  • Discontinued Brain cancer; Coronary artery restenosis; Heart failure; Lung cancer; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 12 Jul 2018 AbbVie completes a phase II trial for Diabetes nephropathies in Germany, Italy, Spain, USA(NCT02118714)
  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2017 AbbVie terminates the phase III SONAR trial in Diabetic nephropathies (Adjunctive treatment) in USA, United Kingdom, Taiwan, Canada, Japan, Puerto Rico, Ukraine, Turkey, Switzerland, Sweden, Spain, South Africa, Slovakia, Singapore, Russia, Romania, Portugal, Poland, Peru, New Zealand, Mexico, Netherlands, Malaysia, South Korea, Italy, Israel, Ireland, Hong Kong, Greece, Germany, France, Finland, Denmark, Czech Republic, China, Chile, Brazil, Belgium, Argentina, Australia and Austria (PO) (NCT01858532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top